The stent is intended for the treatment of aortic arch disease. Credit: A. M. D.

Cardiac and vascular surgery company CryoLife has secured CE Mark for its hybrid stent graft system, E-vita Open NEO.

The system helps to treat aortic arch disease, which includes aortic aneurysms, as well as aortic dissections that occur instantaneously without symptoms.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Every year, around 7,000 patients receive surgical treatment for thoracic aortic arch disease in Europe, the Middle East and Africa.

Many patients having an aneurysm or dissection in the aortic arch also acquire a dissected or aneurysmal descending thoracic aorta.

The treatment of these conditions often involves a two-stage procedure, one to repair the arch and the next to restore the descending thoracic aorta.

CryoLife’s hybrid stent graft technologies, which include the E-vita Open NEO and the E-vita Open Plus, provide one-stage procedure treatment for such conditions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These technologies, which combine the surgical arch repair and the endovascular descending thoracic repair, deliver a cost-effective solution for the health system and enable the patient to avoid a second surgery.

CryoLife chairman, president and CEO Pat Mackin said: “We are pleased to have received CE Mark for E-vita Open NEO, our newest hybrid stent-graft technology for aortic arch and descending thoracic aorta repair.

“This new design features a single tri-branched vessel that enhances ease-of-use and implantation that reduces surgical time and allows for a potentially safer procedure, thereby increasing the likelihood that more patients can benefit from the procedure and patient access to these therapies.”

CryoLife anticipates that the E-vita Open NEO will be used together with JOTEC’S thoracic stent graft offering, E-nya in the treatment of aortic arch disease.

Last month, the company’s On-X Ascending Aortic Prosthesis (AAP) secured CE Mark, enabling its resumed redistribution in Europe.